Hong Kong Electronic Equipment and Components Stock News

HBM Holdings (SEHK:2142) shares have been in focus after the company signed an exclusive license and equity partnership with Solstice Oncology, centered on its clinical asset HBM4003 outside Greater China. See our latest analysis for HBM Holdings. The Solstice agreement arrives as momentum in HBM Holdings' shares has picked up again, with a 1 day share price return of 4.41% and 7 day share price return of 8.12%, while the 1 year total shareholder return of 123.82% and 3 year total shareholder...

Hua Hong Semiconductor (SEHK:1347) is in focus after reporting fourth quarter 2025 results that moved back to net profitability and issuing first quarter 2026 revenue guidance that gives investors clearer near term expectations. See our latest analysis for Hua Hong Semiconductor. Those results sit against a mixed recent trading pattern, with a 4.51% 1 day share price return and a 37.91% 90 day share price return. The 1 year total shareholder return of 137.39% highlights how strongly sentiment...

CARsgen Therapeutics Holdings (SEHK:2171) has entered new cooperation agreements to build a commercial CAR T-cell manufacturing base in Shanghai’s Jinshan District, supporting its existing therapies, late-stage candidates and future allogeneic products. See our latest analysis for CARsgen Therapeutics Holdings. The cooperation news lands as CARsgen’s share price sits at HK$16.14, with a 1-day share price return of 3.33% and 7-day share price return of 7.10%. The 1-year total shareholder...

InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs. See our latest analysis for InnoCare Pharma. The new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...

CEO retirement and board changes put ASMPT in focus ASMPT (SEHK:522) has drawn investor attention after announcing that long serving Group CEO Robin Gerard Ng Cher Tat will retire and not seek re election as director, with Executive Director Guenter Walter Lauber also set to depart after the upcoming AGM. See our latest analysis for ASMPT. The leadership changes come as ASMPT’s share price has moved to HK$110.3, with a 5.15% 1 day and 50.48% 90 day share price return, while the 1 year total...

Why Lenovo Group Stock Is On Investors’ Radar Today Lenovo Group (SEHK:992) has drawn investor attention after a period where the share price has moved higher over the past month but remains lower over the past year. With the stock recently closing at HK$9.37 and multi year returns still positive, many holders are reassessing how its current valuation lines up with the company’s earnings profile and growth in both revenue and net income. See our latest analysis for Lenovo Group. Recent moves...

China Medical System Holdings (SEHK:867) has drawn fresh attention after securing exclusive mainland China distribution rights for Lidoderm lidocaine cataplasms and forming an AI-focused drug discovery partnership with Insilico Medicine across multiple R&D programs. See our latest analysis for China Medical System Holdings. The stock’s recent momentum has been firm, with a 12.45% 1 month share price return and 17.77% year to date share price return. The 1 year total shareholder return of...

If you are wondering whether BYD at around HK$100.10 is a bargain or just fairly priced, you are not alone. That is exactly what this article will help you unpack. The stock has returned 2.4% over the last 7 days, 0.5% over 30 days, 1.4% year to date, but is still showing a 21.9% decline over 1 year while sitting on gains of 43.8% over 3 years and 45.6% over 5 years. Recent headlines around BYD have focused on its expanding presence in electric vehicles and batteries, as well as ongoing...

China Resources Land (SEHK:1109) has released its January 2026 operating update, reporting contracted sales of about RMB 11.65b and recurring revenue of RMB 4.51b, giving investors a fresh monthly read on business activity. See our latest analysis for China Resources Land. The January update comes after a solid stretch of gains, with a 1-month share price return of 10.42% and year to date share price return of 12.41%. The 1-year total shareholder return of 31.18% suggests momentum has been...

Tencent Holdings after recent share price weakness Tencent Holdings (SEHK:700) has seen its share price fall around 12% over the past month and about 16% over the past 3 months, prompting investors to reassess what they are paying for its earnings and growth profile. See our latest analysis for Tencent Holdings. Looking beyond the recent pullback, Tencent Holdings’ 30 day share price return of 12.27% and year to date share price return of 16.21% both point to fading momentum, even though the...

Tencent Holdings (SEHK:700) has backed Chinese large language model developer Moonshot, which has gained rapid traction in the AI sector. The company is also an investor in Maya, a fintech firm that is preparing for a potential US IPO as it seeks international expansion. The US Department of Defense recently named, then removed, Tencent from a list of companies it alleged were linked to China’s military, drawing fresh regulatory attention. Tencent operates across consumer internet, gaming,...

Global markets have recently experienced volatility, with U.S. stocks declining amid concerns over AI disruptions and a mixed economic outlook from various regions. Despite these fluctuations, investors continue to seek opportunities that balance value and growth potential. Penny stocks, though an outdated term, remain relevant for those interested in smaller or newer companies with strong financials that may offer significant returns. In this article, we explore three such penny stocks that...

Guidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance, indicating at least RMB 2,500 million in revenue and RMB 150 million in net profit for the year. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The earnings guidance lands after a strong run in the share price, with a 30 day share price return of 25.19% and a year to date gain of 28.12%...

Insilico Medicine Cayman TopCo announced a new partnership with China Medical System Holdings SEHK:3696 to collaborate on AI powered drug discovery and development. The company also nominated ISM5059, an NLRP3 targeted drug candidate discovered using its AI platform, for preclinical development. These updates follow recent FDA IND approval for another AI created drug in Insilico Medicine's pipeline. For you as an investor, these moves sit at the intersection of AI and pharmaceuticals, where...

Q Technology (Group) (SEHK:1478) has released its January 2026 operating update, reporting monthly sales volumes of 44,071,000 camera modules and 19,741,000 fingerprint recognition modules. This provides investors with a fresh data point on current demand. See our latest analysis for Q Technology (Group). At a share price of HK$8.82, Q Technology (Group) has a 1-year total shareholder return of 12.98% and a 3-year total shareholder return of 86.90%, even though its 30-day share price return...

As global markets grapple with concerns over AI disruptions and mixed economic signals, Asian markets have shown resilience, with Japan's stock indices experiencing significant gains following political developments. In this environment, dividend stocks in Asia offer a compelling option for investors seeking steady income streams; these stocks can provide a buffer against market volatility while potentially yielding attractive returns.

If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools. The stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity. Recent trading interest has been shaped by ongoing attention on the biotech and...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Sinofert Holdings Limited has announced that, effective 13 February 2026, Mr. Su Fu resigned as non-executive director and Chairman, with industry veteran Mr. Zhang Xuegong appointed as executive director, Chairman of the Board and head of the strategy committee. This leadership shift brings the group’s fertilizer, chemical and seed businesses under a chairman who previously held senior roles across Sinochem’s agricultural value chain, potentially reshaping how Sinofert aligns with its...

Minth Group (SEHK:425) has drawn fresh attention after announcing two North American joint ventures: one focused on aluminum body frame parts in Canada and another on humanoid robot joint modules in the United States. See our latest analysis for Minth Group. The recent North American joint venture announcements align with strong momentum in the stock, with a 36.28% 1-month share price return and a very large 1-year total shareholder return, suggesting investors are reassessing Minth Group's...

As global markets navigate the complexities of AI disruption and fluctuating economic indicators, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to provide potential value for those willing to explore beyond mainstream investments. Despite the term's outdated connotations, these stocks can offer significant growth when backed by strong financials. In this article, we explore...

Bank of East Asia (SEHK:23) has drawn investor attention after reporting full year 2025 earnings, with lower net income and a reduced second interim dividend, alongside additional impairment charges and a one off loss at associate Guotong Trust. See our latest analysis for Bank of East Asia. The latest results and dividend cut arrived alongside sharp price swings, with a 7.57% 1 day share price return after the announcement, a 30 day share price return of 11.18%, and a 1 year total...

AIA Group Limited has appointed Ms. Shulamite N K Khoo and Mr. Ku Man as Independent Non-executive Directors to its board, effective 5 February 2026, drawing on their extensive experience across Asian financial services, technology and human capital management. The addition of Ms. Khoo, a former AIA Group Chief Human Resources Officer, and Mr. Ku, Chairman of WeBank, strengthens the board’s governance depth and digital financial expertise at a time when regional insurers are adapting to...

CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory clearance to begin clinical trials for two long acting drug candidates targeting obesity, weight related conditions, and post operative pain. See our latest analysis for CSPC Pharmaceutical Group. The recent regulatory clearances arrive after a strong run, with CSPC Pharmaceutical Group’s 90 day share price return of 35.40% and 1 year total shareholder return of 118.26% pointing to building momentum...